Accuvein Inc.

Accuvein Inc., doing business as Accuvein LLC, manufactures and sells infrared vein visualization systems to federal healthcare agencies as a prime contractor on a GSA Schedule and through direct purchase orders. The company is a for-profit manufacturer headquartered in Medford, New York, holding a $5 million ceiling Medical Equipment and Supplies GSA Schedule contract (FSS-65-II-A) that runs through August 2030 and competes predominantly under full-and-open procurements with occasional Total Small Business set-asides.

Accuvein's core capability is the AV500 infrared vein visualization system and related accessories—devices that project vein maps onto patient skin to assist healthcare professionals in locating peripheral veins for intravenous catheter insertion, phlebotomy, and other vascular access procedures. The systems typically ship with charging cradles, power supplies, one to two years of support, and optional wheeled stands. Recent representative awards include a $101.6 thousand delivery order from Veterans Integrated Service Network 21 for near-infrared vein visualization finding systems (August 2026); a $79.7 thousand order from Veterans Integrated Service Network 8 (September 2026); and a $24.9 thousand order from Veterans Integrated Service Network 22 (September 2026). The company has also sold to the National Institutes of Health Clinical Center (two recent awards totaling roughly $62.5 thousand) and the Defense Health Agency, demonstrating reach beyond VA networks.

Customer concentration reflects a dominant foothold in the Department of Veterans Affairs healthcare system. The Veterans Health Administration and its regional networks (VISNs) collectively account for most awards and dollar volume—VA VISN 12 anchors the portfolio at $13.6 million across eight awards, with VA Headquarters contributing $3.4 million across three awards. VISNs 7, 8, 10, 4, 5, and 21 each hold multiple orders in the $200-$650 thousand range. The Indian Health Service and the Defense Health Agency together represent secondary but sustained customer bases. The top five customer entities by potential value account for 85% of combined portfolio value, indicating tight VA concentration.

All 217 awards in the source data are prime contracts—no subcontract footprint. The GSA Medical Equipment and Supplies schedule (FSS-65-II-A) is the dominant vehicle, carrying 197 task orders valued at $5 million combined. A second IDV (36C10G18D0080) carries three task orders worth $1.7 million; the remaining orders flow as direct purchase orders to individual VISNs and other agencies. Activity declined from twelve awards in 2022 to three in 2025, with a slight uptick to six awards in 2026. Only four awards are scheduled to complete within the next twenty-four months, carrying a combined potential value of $248 thousand—a minimal recompete cliff. Primary NAICS codes are Electromedical and Electrotherapeutic Apparatus Manufacturing (178 awards) and Surgical and Medical Instrument Manufacturing (37 awards), with PSC coding concentrated in Medical and Surgical Instruments, Equipment, and Supplies (184 awards).

AccuVein has a contract with the GSA. AccuVein develops simple solutions to improve vascular access outcomes for patients undergoing IV therapy, venous access procedures, or other treatments. The company has developed the only class 1, real-time, laser-based device that uses near-infrared (NIR) to help clinicians see superficial veins, valves, and bifurcations for better-informed decision making and accurate needle placement. When clinicians use an AccuVein device for pre-insertion assessment, they can rapidly identify optimal vein targets. This not only dramatically increases first attempt success and reduces escalation calls, but it also helps ensure that catheters last for the duration of therapy. With its patented True Center technology, AccuVein is the first and only vein visualization device that is permanently aligned and does not require calibration, allowing clinicians to accurately view the centerline of the vein with each use.